Review of the experience of using herbal drugs for the treatment of acute rhinosinusitis from the standpoint of evidence-based medicine

Cover Page

Cite item

Full Text

Abstract

General background. The overuse of antibiotics, including for the treatment of uncomplicated acute rhinosinusitis (ARS), has contributed to the emergence of antibiotic-resistant bacterial strains and has led to the need for alternative therapies. The review provides an assessment of the quality of evidence for the use of phytotherapy in ARS in order to determine its position among other therapies and future directions of research. The MEDLINE database was searched for randomized controlled studies of Sinupret®, Pelargonium sidoides extract (pelargonium), Cyclamen europaeum (cyclamen), cineole and GeloMyrtol®. We also searched for results from studies of a nasal spray with N-acetylcysteine and mometasone furoate (MF) in order to compare the effectiveness of herbal preparations with these traditional agents indicated for ARS. Main content. The strongest evidence was obtained for Sinupret®, followed by Pelargonium sidoides extract. Their use for treatment of ARS is supported by double-blind, placebo-controlled studies demonstrating both clinical efficacy and safety. Comparisons with traditional treatments such as topical glucocorticosteroids were found only for Sinupret® and they showed comparable efficacy, but in a small group of patients. For other herbal drugs, the pooled level of evidence was low. The search identified 2 small, placebo-controlled, randomized studies of cyclamen nasal spray. In two studies, it was impossible to make conclusions about the safety and efficacy of cyclamen nasal spray and reported no efficacy of cyclamen in reducing symptoms. We found only one randomized placebo-controlled study of GeloMyrtol® and cineol. The mention studies have showed a reduction in ARS symptoms with these two drugs, but larger studies are needed to confirm these findings. There are few studies that directly compared herbal drugs. In one randomized study, cineol was compared with Sinupret®, but the results need to be confirmed in further studies. Studies of N-acetylcysteine are limited to small clinical trials, while the use of MF nasal spray has been confirmed with results comparable in evidence to Sinupret® for the respective indications. Conclusions. There are modern studies that demonstrate the efficacy and safety of herbal drugs for ARS treatment. Given that the evidence for Sinupret® is the strongest and comparable to that for the widely available topical corticosteroid, MF, Sinupret could be considered for the treatment of uncomplicated ARS.

About the authors

Claus Bachert

University Hospital Ghent

Email: claus.bachert@ugent.be
профессор, глава лаборатории исследования верхних дыхательных путей Ghent, Belgium

References

  1. Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. Rhinology. 2012;50:1-12. doi: 10.4193/Rhino50E2
  2. Worrall G. Acute sinusitis. Can Fam Physician. 2011;57:56577.
  3. Orlandi RR, Kingdom TT, Hwang PH. International consensus statement on allergy and rhinology: rhinosinusitis executive summary. Int Forum Allergy Rhinol. 2016;6(Suppl. 1):S3-21. doi: 10.1002/alr.21694
  4. Sharma P, Finley R, Weese S, et al. Antibiotic prescriptions for outpatient acute rhinosinusitis in Canada, 2007-2013. PLoS One. 2017;12:e0181957. doi: 10.1371/journal.pone.0181957
  5. Eisenberg DM, Davis RB, Ettner SL, et al. Trends in alternative medicine use in the United States, 19901997: results of a follow-up national survey. JAMA. 1998;280:1569-75. doi: 10.1001/jama.280.18.1569
  6. Guo R, Pittler MH, Ernst E. Herbal medicines for the treatment of allergic rhinitis: a systematic review. Ann Allergy Asthma Immunol. 2007;99:483-95. doi: 10.1016/S1081-1206(10)60375-4
  7. Koch AK, Klose P, Lauche R, et al. A systematic review of phytotherapy for acute rhinosinusitis. Forsch Komplementmed. 2016;23:165-9. doi: 10.1159/000447467
  8. Macchi A, Terranova P, Castelnuovo P. Recurrent acute rhinosinusitis: a single blind clinical study of N-acetylcysteine vs ambroxol associated to corticosteroid therapy. Int J Immunopathol Pharmacol. 2012;25:207-17. doi: 10.1177/039463201202500123
  9. Neubauer N, Marz RW. Placebo-controlled, randomized double-blind clinical trial with Sinupret(R) sugar coated tablets on the basis of a therapy with antibiotics and decongestant nasal drops in acute sinusitis. Phytomedicine. 1994;1:177-81. doi: 10.1016/S0944-7113(11)80061-9
  10. Rossi A, Dehm F, Kiesselbach C, et al. The novel Sinupret(R) dry extract exhibits antiinflammatory effectiveness in vivo. Fitoterapia. 2012;83:715720. doi: 10.1016/j.fitote.2012.02.008
  11. Marz RW, Ismail C, Popp MA. Profile and effectiveness of a phytogenic combination preparation for treatment of sinusitis. Wien Med Wochenschr. 1999;149:202-8.
  12. Melzer J, Saller R, Schapowal A, Brignoli R. Systematic review of clinical data with BNO-101 (Sinupret) in the treatment of sinusitis. Forsch Komplementmed. 2006;13:78-87. doi: 10.1159/000091969
  13. Jund R, Mondigler M, Stammer H, et al. Herbal drug BNO 1016 is safe and effective in the treatment of acute viral rhinosinusitis. Acta Otolaryngol. 2015;135:42-50. doi: 10.3109/00016489.2014.952047
  14. Jund R, Mondigler M, Steindl H, et al. Clinical efficacy of a dry extract of five herbal drugs in acute viral rhinosinusitis. Rhinology. 2012;50:417-26. doi: 10.4193/Rhino12.015
  15. Jund R, Mondigler M, Steindl H, et al. Clinical efficacy of a herbal drug combination in acute viral rhinosinusitis. MMW Fortschr Med. 2015;157:6-11. doi: 10.1007/s15006-015-2934-4
  16. Passali D, Loglisci M, Passali GC, et al. A prospective open-label study to assess the efficacy and safety of a herbal medicinal product (Sinupret) in patients with acute rhinosinusitis. ORL J Otorhinolaryngol Relat Spec. 2015;77:27-32. D0I:10.1159/000370123
  17. Weber U, Luedtke R, Friese KH, et al. A non-randomised pilot study to compare complementary and conventional treatments of acute sinusitis. Forsch Komplementarmed Klass Naturheilkd. 2002;9:99-104. doi: 10.1159/000057271
  18. Schoetz K, Erdelmeier C, Germer S, Hauer H. A detailed view on the constituents of EPs 7630. Planta Med. 2008;74:667-74. doi: 10.1055/s-2008-1074515
  19. Bladt S, Wagner H. From the Zulu medicine to the European phytomedicine Umckaloabo. Phytomedicine. 2007;14(Suppl. 6):2-4. DOI:10.1016/j. phymed.2006.11.030
  20. Kayser O, Kolodziej H, Kiderlen AF. Immunomodulatory principles of Pelargonium sidoides. Phytother Res. 2001;15:122-6. doi: 10.1002/ptr.785
  21. Michaelis M, Doerr HW, Cinatl J Jr. Investigation of the influence of EPs(R) 7630, a herbal drug preparation from Pelargonium sidoides, on replication of a broad panel of respiratory viruses. Phytomedicine. 2011;18:384-6. doi: 10.1016/j.phymed.2010.09.008
  22. Lizogub VG, Riley DS, Heger M. Efficacy of a Pelargonium sidoides preparation in patients with the common cold: a randomized, double blind, placebo-controlled clinical trial. Explore (NY). 2007;3:573-84. D0I:10.1016/j.explore.2007.09.004
  23. Riley DS, Lizogub VG, Zimmermann A, et al. Efficacy and tolerability of high-dose pelargonium extract in patients with the common cold. Altern Ther Health Med. 2018;24:16-26.
  24. Bachert C, Schapowal A, Funk P, Kieser M. Treatment of acute rhinosinusitis with the preparation from Pelargonium sidoides EPs 7630: a randomized, double-blind, placebo-controlled trial. Rhinology. 2009;47:51-8.
  25. Peric A, Gacesa D, Barac A, et al. Herbal drug EPs 7630 versus amoxicillin in patients with uncomplicated acute bacterial rhinosinusitis: a randomized, open-label study. Ann Otol Rhinol Laryngol. 2020;129:969-76. doi: 10.1177/0003489420918266
  26. Mullol J, Crespo C, Carre C, Brosa M. Pharmacoeconomics of Cyclamen europaeum in the management of acute rhinosinusitis. Laryngoscope. 2013;123:2620-5. doi: 10.1002/lary.24167
  27. Pfaar O, Mullol J, Anders C, et al. Cyclamen europaeum nasal spray, a novel phytotherapeutic product for the management of acute rhinosinusitis: a randomized double-blind, placebo-controlled trial. Rhinology. 2012;50(1):37-44. doi: 10.4193/Rhino10.096
  28. Ponikau JU, Hamilos DL, Barreto A, et al. An exploratory trial of Cyclamen europaeum extract for acute rhinosinusitis. Laryngoscope. 2012;122:1887-92. doi: 10.1002/lary.23366
  29. Gedevanishvili MD, Gogitidze NM, Sikharulidze IS. Reflex mechanisms of nasoparanasal secretion in administration of sinuforte. Vestn Otorinolaringol. 2007;(3):54-5.
  30. Zalmanovici Trestioreanu A, Barua A, Pertzov B. Cyclamen europaeum extract for acute sinusitis. Cochrane Database SystRev. 2018;5:CD011341. D0I:10.1002/14651858.CD011341.pub2
  31. Gottschlich S, Roschmann K, Candler H. Phytomedicines in acute rhinosinusitis: a prospective, non-interventional parallel-group trial. Adv Ther. 2018;35:1023-34. doi: 10.1007/s12325-018-0736-7
  32. Rantzsch U, Vacca G, Duck R, Gillissen A. Anti-inflammatory effects of Myrtol standardized and other essential oils on alveolar macrophages from patients with chronic obstructive pulmonary disease. Eur J Med Res. 2009;14(Suppl. 4):205-9. doi: 10.1186/2047-783x-14-s4-205
  33. Christoph F, Kaulfers PM, Stahl-Biskup E. In vitro evaluation of the antibacterial activity of betatriketones admixed to Melaleuca oils. Planta Med. 2001;67:768-71. doi: 10.1055/s-2001-18350
  34. Behrbohm H, Kaschke O, Sydow K. Effect of the phytogenic secretolytic drug Gelomyrtol forte on mucociliary clearance of the maxillary sinus. Laryngorhinootologie. 1995;74:733-7. doi: 10.1055/s-2007-997835
  35. Meister R, Wittig T, Beuscher N, de Mey C. Efficacy and tolerability of myrtol standardized in longterm treatment of chronic bronchitis. A double-blind, placebo-controlled study. Study Group Investigators. Arzneimittelforschung. 1999;49:351-8. doi: 10.1055/s-0031-1300426
  36. Gillissen A, Wittig T, Ehmen M, et al. A multi-centre, randomised, double-blind, placebo-controlled clinical trial on the efficacy and tolerability of GeloMyrtol(R) forte in acute bronchitis. Drug Res (Stuttg). 2013;63:19-27. doi: 10.1055/s-0032-1331182
  37. Federspil P, Wulkow R, Zimmermann T. Effects of standardized Myrtol in therapy of acute sinusitis - results of a double-blind, randomized multicenter study compared with placebo. Laryngorhinootologie. 1997;76:2377. doi: 10.1055/s-2007-997381
  38. Kehrl W, Sonnemann U, Dethlefsen U. Therapy for acute nonpurulent rhinosinusitis with cineole: results of a double-blind, randomized, placebo-controlled trial. Laryngoscope. 2004;114:738-42. DOI:10.1097/ 00005537-200404000-00027
  39. Paparoupa M, Gillissen A. Is Myrtol(R) standardized a new alternative toward antibiotics? Pharma-cogn Rev. 2016;10:143-6. doi: 10.4103/0973-7847.194045
  40. Aldoghaim FS, Flematti GR, Hammer KA. Antimicrobial activity of several ineole-rich Western Australian Eucalyptus essential oils. Microorganisms. 2018;6. doi: 10.3390/microorganisms6040122
  41. Yadav N, Chandra H. Suppression of inflammatory and infection responses in lung macrophages by eucalyptus oil and its constituent 1,8-cineole: role of pattern recognition receptors TREM-1 and NLRP3, the MAP kinase regulator MKP-1, and NFkappaB. PLoS One. 2017;12:e0188232. doi: 10.1371/journal.pone.0188232
  42. Juergens UR. Anti-inflammatory properties of the monoterpene 1.8-cineole: urrent evidence for co-medication in inflammatory airway diseases. Drug Res (Stuttg). 2014;64:638-46. doi: 10.1055/s-0034-1372609
  43. Tesche S, Metternich F, Sonnemann U, et al. The value of herbal medicines in the treatment of acute non-purulent rhinosinusitis. Results of a double-blind, randomised, controlled trial. Eur Arch Otorhinolaryngol. 2008;265:1355-9. doi: 10.1007/s00405-008-0683-z
  44. Bachert C, Thakur M, Weyers S, et al. Reporting clinical trial results of phytomedicines in acute rhinosinusitis: letter to the editor regarding Gottschlich S, Roschmann K, Candler H. Adv Ther (2018); 35:1023-1034. doi: 10.1007/s12325-018-0736-7. Adv Ther. 2019;36:1011-3. doi: 10.1007/s12325-019-00933-6
  45. Passali D, Spinosi MC, Crisanti A, Bellussi LM. Mometasone furoate nasal spray: a systematic review. Multidiscip Respir Med. 2016;11:18. doi: 10.1186/s40248-016-0054-3
  46. Meltzer EO, Charous BL, Busse WW, et al. Added relief in the treatment of acute recurrent sinusitis with adjunctive mometasone furoate nasal spray. The Nasonex Sinusitis Group. J Allergy Clin Immunol. 2000;106:630-7. doi: 10.1067/mai.2000.109056
  47. Nayak AS, Settipane GA, Pedinoff A, et al. Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Ann Allergy Asthma Immunol. 2002;89:271-8. doi: 10.1016/S1081-1206(10)61954-0
  48. Meltzer EO, Bachert C, Staudinger H. Treating acute rhinosinusitis: comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo. J Allergy Clin Immunol. 2005;116:1289-95. doi: 10.1016/j.jaci.2005.08.044
  49. Bachert C, Meltzer EO. Effect of mometasone furoate nasal spray on quality of life of patients with acute rhinosinusitis. Rhinology. 2007;45:190-6.
  50. Meltzer EO, Gates D, Bachert C. Mometasone furoate nasal spray increases the number of minimal-symptom days in patients with acute rhinosinusitis. Ann Allergy Asthma Immunol. 2012;108:275-9. doi: 10.1016/j.anai.2012.01.015
  51. Zalmanovici Trestioreanu A, Yaphe J. Intranasal steroids for acute sinusitis. Cochrane Database Syst Rev. 2013:CD005149. DOI:10.1002/ 14651858.CD005149.pub4
  52. Blasi F, Page C, Rossolini GM, et al. The effect of N-acetylcysteine on biofilms: implications for the treatment of respiratory tract infections. Respir Med. 2016;117:190-7. doi: 10.1016/j.rmed.2016.06.015
  53. Sadowska AM, Verbraecken J, Darquennes K, De Backer WA. Role of N-acetylcysteine in the management of COPD. Int J Chron Obstruct Pulmon Dis. 2006;1:425-34. doi: 10.2147/copd.2006.1.4.425
  54. Bahtouee M, Monavarsadegh G, Ahmadipour M, et al. Acetylcysteine in the treatment of subacute sinusitis: a double-blind placebo-controlled clinical trial. Ear Nose Throat J. 2017;96:E7-11. doi: 10.1177/014556131709600102.

Copyright (c) 2021 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies